This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Depend on DuPont to Buy 5 Top-Ranked Healthy Stocks
by Sanghamitra Saha
Why you should depend on the DuPont technique to pick solid profit-generating stocks.
Strong Brands to Keep Hain Celestial (HAIN) Cheering in 2021
by Zacks Equity Research
Hain Celestial (HAIN) gains from strong brand penetration across North America and International segments. Markedly, at-home dining trends are adding gleam to the stock.
Kellogg's (K) MorningStar Farms & Dunkin' Launch Meatless Sandwich
by Zacks Equity Research
Kellogg's (K) MorningStar Farms teams up with Dunkin' to introduce a meatless yet flavorful product ¿¿¿ the Southwest Veggie Power Breakfast Sandwich.
The Zacks Analyst Blog Highlights: B&G Foods, Hain Celestial, Medifast and United Natural Foods
by Zacks Equity Research
The Zacks Analyst Blog Highlights: B&G Foods, Hain Celestial, Medifast and United Natural Foods
4 Food Stocks Up More Than 50% in 2020 With Room to Grow
by Vrishali Bagree
Several food companies are gaining on higher at-home consumption amid the pandemic. Also, focus on innovation and other brand-building efforts has been backing growth for B&G Foods (BGS), Hain Celestial (HAIN), Medifast (MED) and United Natural (UNFI).
The Zacks Analyst Blog Highlights: MACOM Tech, CrowdStrike, Zscaler, CareDx and Medifast
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MACOM Tech, CrowdStrike, Zscaler, CareDx and Medifast
Smucker (SJM) Gains on Pandemic-Led Demand, Cost Concerns Stay
by Zacks Equity Research
Smucker (SJM) has been gaining on increased demand owing to the pandemic-led higher at-home consumption. However, the company expects a rise in SD&A expenses in fiscal 2021.
5 Stocks With Unstoppable Growth to Buy in 2021
by Rajani Lohia
Investing in stocks which have outpaced the market in 2020, defying the impacts of the COVID-19 outbreak, and have the potential for greater returns in 2021 is advisable.
Is MEDIFAST INC (MED) Outperforming Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Is (MED) Outperforming Other Consumer Staples Stocks This Year?
Here's Why Medifast (MED) is Likely to Sustain Solid Run in 2021
by Zacks Equity Research
Medifast (MED) has been benefiting from strength in OPTAVIA along with a focus on core growth strategies even amid the pandemic.
Mondelez (MDLZ) Gains on Effective Saving Efforts & Buyouts
by Zacks Equity Research
Mondelez (MDLZ) is benefiting from its impressive savings plan and brand-building efforts. However, unfavorable currency rates are headwinds.
General Mills (GIS) Q2 Earnings & Sales Top Estimates, Up Y/Y
by Zacks Equity Research
General Mills' (GIS) second-quarter fiscal 2021 earnings and sales increase year over year. Results reflect rising demand stemming from increased at-home consumption amid the pandemic.
McCormick (MKC) Benefits From Brand Strength, Saving Plans
by Zacks Equity Research
McCormick (MKC) is witnessing higher demand thanks to increased-at home consumption amid COVID-19. Also, the company's lucrative acquisitions are worth mentioning.
Smucker (SJM) Unveils Strategic Growth Pillars, Retains View
by Zacks Equity Research
Smucker (SJM) lays down four pillars of operational priorities for the next 12-18 months to drive growth. Also, the company provides long-term financial targets.
5 Top-Ranked Stocks Empowered by DuPont Analysis
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation and bet on these five stocks.
United Natural's (UNFI) Q1 Earnings Miss Estimates, Sales Up
by Zacks Equity Research
United Natural's (UNFI) first-quarter fiscal 2021 results reflect higher sales, courtesy of robust consumer demand and cross-selling benefits. Also, earnings increase year over year.
Is MEDIFAST INC (MED) Stock Outpacing Its Consumer Staples Peers This Year?
by Zacks Equity Research
Is (MED) Outperforming Other Consumer Staples Stocks This Year?
Medifast (MED) Up 30.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast (MED) Up More Than 75% YTD: Will Momentum Stay?
by Zacks Equity Research
Medifast (MED) has been gaining on robust performance of OPTAVIA. Also, the company has certain planned investments for growth, though they are likely to affect margins.
Medifast (MED) Q3 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
Medifast's (MED) third-quarter 2020 results reflect increased earnings and sales. Robust OPTAVIA performance, courtesy of rise in active earning coaches, fuels results.
Medifast (MED) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 16.87% and 10.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's How Medifast (MED) Looks Just Ahead of Q3 Earnings
by Zacks Equity Research
Medifast's (MED) third-quarter results are likely to reflect gains from consumers' increased inclination toward health products amid the pandemic. However, high costs are a concern.
Mondelez (MDLZ) Queued for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Higher demand in developed markets amid COVID-19 is likely to get reflected in Mondelez's (MDLZ) third-quarter 2020 numbers. However, escalated costs are a concern.
Estee Lauder (EL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Adverse impacts of coronavirus-induced temporary store closures and sluggishness in travel retail are likely to get reflected in Estee Lauder's (EL) first-quarter fiscal 2021 performance.
Here's How Pilgrim's Pride (PPC) Looks Ahead of Q3 Earnings
by Zacks Equity Research
Macroeconomic headwinds in Mexico and soft demand in foodservice channels are likely to get reflected in Pilgrim's Pride's (PPC) third-quarter performance. However, favorable inputs costs bode well.